Pacira BioSciences, Inc. - Asset Resilience Ratio
Pacira BioSciences, Inc. (PCRX) has an Asset Resilience Ratio of 4.79% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Pacira BioSciences, Inc.'s Asset Resilience Ratio has changed over time. Check PCRX capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Pacira BioSciences, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PCRX company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $57.87 Million | 4.79% |
| Total Liquid Assets | $57.87 Million | 4.79% |
Asset Resilience Insights
- Limited Liquidity: Pacira BioSciences, Inc. maintains only 4.79% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pacira BioSciences, Inc. Industry Peers by Asset Resilience Ratio
Compare Pacira BioSciences, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401 |
Drug Manufacturers - Specialty & Generic | 5.09% |
|
KPC Pharmaceuticals Inc
SHG:600422 |
Drug Manufacturers - Specialty & Generic | 16.37% |
Annual Asset Resilience Ratio for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Pacira BioSciences, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.31% | $79.88 Million | $1.26 Billion | -7.06pp |
| 2024-12-31 | 13.38% | $207.84 Million | $1.55 Billion | +5.42pp |
| 2023-12-31 | 7.96% | $125.28 Million | $1.57 Billion | -3.02pp |
| 2022-12-31 | 10.98% | $184.51 Million | $1.68 Billion | +7.56pp |
| 2021-12-31 | 3.41% | $70.83 Million | $2.08 Billion | -29.67pp |
| 2020-12-31 | 33.09% | $421.70 Million | $1.27 Billion | +7.37pp |
| 2019-12-31 | 25.72% | $213.72 Million | $831.07 Million | -10.68pp |
| 2018-12-31 | 36.40% | $250.93 Million | $689.35 Million | -4.53pp |
| 2017-12-31 | 40.93% | $257.22 Million | $628.37 Million | +6.03pp |
| 2016-12-31 | 34.91% | $136.65 Million | $391.47 Million | +8.73pp |
| 2015-12-31 | 26.17% | $101.98 Million | $389.62 Million | -10.36pp |
| 2014-12-31 | 36.54% | $119.14 Million | $326.07 Million | +1.42pp |
| 2013-12-31 | 35.12% | $59.64 Million | $169.82 Million | +7.52pp |
| 2012-12-31 | 27.60% | $30.92 Million | $112.05 Million | +1.18pp |
| 2011-12-31 | 26.42% | $29.98 Million | $113.49 Million | +24.45pp |
| 2010-12-31 | 1.97% | $1.31 Million | $66.56 Million | -0.79pp |
| 2009-12-31 | 2.77% | $1.22 Million | $43.95 Million | +0.43pp |
| 2008-12-31 | 2.34% | $1.18 Million | $50.54 Million | -- |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more